MBX-2982

· Gilead Sciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MBX-2982, covering 2015-04-17 to 2015-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes [Phase 2]

See pricing